Adjuvant treatment with atezolizumab and bevacizumab prolongs recurrence-free survival, when compared with active surveillance, in patients with hepatocellular carcinoma, a phase 3 study suggests.
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
Researchers sought to determine the relationship between direct radiation dose and inflammation and regional hepatic function after stereotactic body radiation therapy for hepatocellular carcinoma.
The number of people diagnosed with liver cancer is predicted to rise substantially by 2040.
The approval was based on data from the phase 3 TOPAZ-1 trial.
Individuals who are overweight or obese, or who become overweight or obese over time, have a higher risk of liver cancer and biliary tract cancer.
Researchers found that hepatocellular carcinoma surveillance was underutilized among approximately 80% of patients with cirrhosis.
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
Hazard ratio of 1.78 for consumption of one or more SSB/day compared with never consumption for older women.
The risk for kidney failure requiring renal replacement therapy varies by cancer type, with multiple myeloma associated with the highest risk.
